Published in

Centers for Disease Control and Prevention, Emerging Infectious Diseases, 6(7), p. 1069-1069

DOI: 10.3201/eid0706.010633

Centers for Disease Control and Prevention, Emerging Infectious Diseases, 6(6), p. 585-594

DOI: 10.3201/eid0606.000606

Links

Tools

Export citation

Search in Google Scholar

Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.

Journal article published in 2000 by E. M. Muchiri, J. H. Ouma, Y. S. Liang, Charles H. King ORCID, M. J. Doenhoff, G. C. Coles
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly endemic. Our results, derived from treating 4,031 of 7,641 children from 1984 to 1993, indicate substantial year-to- year variation in drug efficacy. However, the pattern of this variation was not consistent with primary or progressive emergence of praziquantel resistance. Mathematical modeling indicated that, at current treatment rates, praziquantel resistance will likely take 10 or more years to emerge.